Semaglutide vs Tirzepatide: Which GLP-1 is Right for You?

If you're considering GLP-1 medications for weight loss, you've likely encountered two main options: semaglutide (brand names Wegovy and Ozempic) and tirzepatide (brand names Zepbound and Mounjaro). Both are highly effective, but they work slightly differently and have different profiles.

How They Work

Semaglutide is a GLP-1 receptor agonist, meaning it mimics the GLP-1 hormone that your body naturally produces. This hormone helps regulate blood sugar, slows gastric emptying, and reduces appetite.

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it targets two hormones instead of one. This dual action may contribute to its potentially higher effectiveness in some studies.

Effectiveness: Head-to-Head Results

The SURMOUNT-5 trial directly compared these medications:

• Tirzepatide: 20.2% average weight loss over 72 weeks
• Semaglutide: 13.7% average weight loss over 72 weeks

However, the new Wegovy HD (7.2mg) has shown results approaching 21%, narrowing the gap.

Side Effects

Both medications share similar side effects, primarily gastrointestinal:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Stomach pain

These side effects are typically most pronounced when starting the medication or increasing dosage, and often improve over time.

Cost Comparison

Without insurance, both medications are expensive at retail pharmacies (around $1,000-1,500/month). Through telehealth providers offering compounded versions, costs can be significantly lower:

• Compounded semaglutide: $149-299/month
• Compounded tirzepatide: $199-399/month

The Verdict

Both semaglutide and tirzepatide are highly effective for weight loss. Tirzepatide shows an edge in head-to-head trials, but semaglutide has a longer track record, more forms available (including the new pill), and is more widely accessible. The best choice depends on your individual health situation, budget, and provider availability.